Redeye comments on G5’s Q4-results which came in close to our expectations.
Redeye believes Sdiptech’s Q4 report and guidance will relieve the soft share price performance seen...
Redeye updates estimates and valuation on Evolution post its Q4-results where we have taken down our...
Redeye leaves a comment on Respiratorious following the announcement of a SEK 45m fully guaranteed r...
Redeye thinks Jondetech's expansion to a software-only offering is good.
Redeye gives a short comment on the announced rights issue and pauses its coverage.
Redeye is encouraged to learn that a health economic analysis carried out by the Swedish Dental and ...
Following Monday's announcement of the Xcimzane licensing deal with Biogen, Redeye is convinced that...
Q4 2021 - ingen kioskvältare Det blev ett svagt avslut på 2021.
Stark omsättningstillväxt men lägre marginal Justerad nettoomsättning i Q4'21 uppgick till 186 mkr (...
Redeye returns with a follow-up note to Genovis’ Q4’21 report.
Redeye provides a preview of its Q4'21 estimates for BONESUPPORT ahead of its report next week.
Plejd växte nettoomsättningen med 31,2 procent. Vi justerar estimat och riktkurs något.
Earlier today, Alzecure reported that the company had received a supportive response from the FDA re...
Redeye comments on Evolution’s Q4 results which came in slightly lower than we expected.
Tjänsteföretaget Coor går ett spännande år till mötes när pandemirestriktionerna avskaffas.
ChromoGenics publicerade idag den 8 februari 2022 sin delårsrapport för fjärde kvartalet 2021.
Utmaningar i värdekedjan kostar Omsättningen i Q4'21 minskade med 6% jämfört med Q4 förra året i en ...
Etteplan reports Q4 results on February 10th, with expectations of rather good growth and margins.
Rapportkommentar Q4 2021 Nettoomsättningen för det fjärde kvartalet uppgick till 15,4 mkr (3,8), med...
